Skip to main content
    I

    Immix Biopharma Inc (IMMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.48
    -0.36 (-4.59%)

    Market Cap: $657.09M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Immix Biopharma Inc (IMMX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Immix Biopharma are Immatics NV (IMTX), Inhibrx Biosciences (INBX) and CorMedix (CRMD). By market cap, Immix Biopharma ranks 7th of the 13 companies on this page; Inhibrx Biosciences (INBX) is the largest at $1.23B.

    Peer Comparison

    IMMX's ROIC of -14.9% is above the peer median of -53.8%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Immix Biopharma (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Immatics NV (IMTX)$972.99MN/A17.7x0.0%N/A33.5%0.00%
    Inhibrx Biosciences, Inc. (INBX)$1.23BN/A610.4x0.0%-66.0%-100.0%0.00%
    CorMedix Inc (CRMD)$370.64M6.3x0.9x15.5%13.9%-47.7%0.00%
    Olema Pharmaceuticals Inc (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    Puma Biotechnology Inc (PBYI)$401.70M15.0x1.6x10.3%N/A1.1%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    MoonLake Immunotherapeutics (MLTX)$1.06BN/AN/A0.0%-54.6%0.0%0.00%
    Cullinan Oncology LLC (CGEM)$667.39MN/AN/A0.0%N/A0.0%0.00%
    Climb Bio Inc (CLYM)$608.53MN/AN/A0.0%N/A0.0%0.00%
    Indaptus Therapeutics Inc (INDP)$422.38MN/AN/A0.0%N/A0.0%0.00%
    DBV Technologies (DBVT)$692.19MN/AN/A0.0%-130.3%-42.9%0.00%
    Entera Bio Ltd (ENTX)$541.57MN/AN/A0.0%-8.5%-100.0%0.00%
    Peer median$635.41M10.7x17.7x0.0%-53.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Immix Biopharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Immatics NV (IMTX)
    Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies...
    IMTX competitors
    Inhibrx Biosciences, Inc. (INBX)
    Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates.
    INBX competitors
    CorMedix Inc (CRMD)
    CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious...
    CRMD competitors
    Olema Pharmaceuticals Inc (OLMA)
    Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development...
    OLMA competitors
    Puma Biotechnology Inc (PBYI)
    Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States...
    PBYI competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    MoonLake Immunotherapeutics (MLTX)
    MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug...
    MLTX competitors
    Cullinan Oncology LLC (CGEM)
    Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients...
    CGEM competitors
    Climb Bio Inc (CLYM)
    Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.
    CLYM competitors
    Indaptus Therapeutics Inc (INDP)
    Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms.
    INDP competitors
    DBV Technologies (DBVT)
    DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products.
    DBVT competitors
    Entera Bio Ltd (ENTX)
    Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies...
    ENTX competitors

    Frequently Asked Questions About IMMX

    Who are Immix Biopharma's main competitors?

    The companies most similar to Immix Biopharma include Immatics NV (IMTX), Inhibrx Biosciences (INBX), CorMedix (CRMD), Olema Pharmaceuticals (OLMA) and Puma Biotechnology (PBYI), listed from the closest match.

    Who is Immix Biopharma's biggest competitor?

    Inhibrx Biosciences (INBX) is the largest of the similar companies at $1.23B; Immatics NV (IMTX) is the closest match by business profile, size, sector and industry.

    How does IMMX stock compare with its competitors?

    IMMX's net margin is 0.0% against a peer median of 0.0%.

    Which of Immix Biopharma's competitors pays a higher dividend?

    Immix Biopharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Immix Biopharma bigger than its competitors?

    No. Immix Biopharma is 7th by market cap among the 13 companies on this page; the largest is Inhibrx Biosciences (INBX) at $1.23B.